148 related articles for article (PubMed ID: 23860481)
1. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.
Technau KG; Lazarus E; Kuhn L; Abrams EJ; Sorour G; Strehlau R; Reubenson G; Davies MA; Coovadia A
Pediatr Infect Dis J; 2013 Aug; 32(8):851-5. PubMed ID: 23860481
[TBL] [Abstract][Full Text] [Related]
2. Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis.
Technau KG; Schomaker M; Kuhn L; Moultrie H; Coovadia A; Eley B; Rabie H; Wood R; Cox V; Vizcaya LS; Muchiri E; Davies MA;
Pediatr Infect Dis J; 2014 Jun; 33(6):617-22. PubMed ID: 24378944
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
4. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A
PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654
[TBL] [Abstract][Full Text] [Related]
5. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
7. Drug Resistance Mutations Among South African Children Living With HIV on WHO-recommended ART Regimens.
Hackett S; Teasdale CA; Pals S; Muttiti A; Mogashoa M; Chang J; Zeh C; Ramos A; Rivadeneira ED; DeVos J; Sleeman K; Abrams EJ
Clin Infect Dis; 2021 Oct; 73(7):e2217-e2225. PubMed ID: 32735012
[TBL] [Abstract][Full Text] [Related]
8. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
Ho S; Wong JG; Ng OT; Lee CC; Leo YS; Lye DCB; Wong CS
AIDS Res Ther; 2020 May; 17(1):23. PubMed ID: 32438914
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of initial differential antiretroviral regimens among HIV patients in Southwest China: comparison from an observational cohort study.
Kang R; Luo L; Chen H; Zhu Q; Liao L; Xing H; Zhu J; Shen Z; Lan G; Tang Z; Shao Y; Yang W; Ruan Y
BMJ Open; 2019 Mar; 9(3):e025666. PubMed ID: 30928945
[TBL] [Abstract][Full Text] [Related]
11. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Sax PE; Tierney C; Collier AC; Daar ES; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Feinberg J; Tashima K; Murphy RL; Fischl MA;
J Infect Dis; 2011 Oct; 204(8):1191-201. PubMed ID: 21917892
[TBL] [Abstract][Full Text] [Related]
12. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Mugavero MJ; May M; Ribaudo HJ; Gulick RM; Riddler SA; Haubrich R; Napravnik S; Abgrall S; Phillips A; Harris R; Gill MJ; de Wolf F; Hogg R; Günthard HF; Chêne G; D'Arminio Monforte A; Guest JL; Smith C; Murillas J; Berenguer J; Wyen C; Domingo P; Kitahata MM; Sterne JA; Saag MS; ; ; ;
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):253-60. PubMed ID: 21857357
[TBL] [Abstract][Full Text] [Related]
14. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
[TBL] [Abstract][Full Text] [Related]
15. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
17. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
Pulido F; Estrada V; Baril JG; Logue K; Schewe K; Plettenberg A; Duiculescu D; Yau L; Vavro C; Lim ML; Pharo C
HIV Clin Trials; 2009; 10(2):76-87. PubMed ID: 19487177
[TBL] [Abstract][Full Text] [Related]
19. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
Potard V; Rey D; Mokhtari S; Frixon-Marin V; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
Antivir Ther; 2007; 12(3):317-24. PubMed ID: 17591021
[TBL] [Abstract][Full Text] [Related]
20. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
Moyle GJ; DeJesus E; Cahn P; Castillo SA; Zhao H; Gordon DN; Craig C; Scott TR;
J Acquir Immune Defic Syndr; 2005 Apr; 38(4):417-25. PubMed ID: 15764958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
